N Engl J Med: Covid-19 patients with thrombosis caused by antiphospholipid antibodies
AURA Biopharm AS is in the preclinical phase of developing AUR-1001 as a first in class pathogenic-tailored drug for the prevention and treatment of thrombosis in patients with Antiphospholipid syndrome (APS). APS is an autoimmune disease where patients produce antiphospholipid antibodies causing thrombosis. In a recent...
Read More